CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China – Nasdaq
|
CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
Nasdaq BASEL, Switzerland, June 19, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that China's State Intellectual … Intellia Therapeutics (NTLA) Receives Patent for CRISPR/Cas … Intellia Therapeutics Announces Patent for CRISPR/Cas Genome … Intellia Therapeutics Inc (NTLA) Expected to Announce Earnings of -$0.41 Per Share |
